98 results about "Erythrocyte membrane" patented technology

Systems and methods for determining the concentration of hemoglobin derivatives in bodily fluids include devices for measuring and comparing the absorption of electromagnetic radiation by cellular and cell-free hemoglobin at two or more wavelengths in the Soret region. Systems and methods for determining erythrocyte membrane fragility include devices for measuring the concentration of at least one cell-free hemoglobin derivative, and using the absorption properties of cellular and cell-free hemoglobin derivatives in the Soret region.

Systems and methods for determining the concentration of hemoglobin derivatives in bodily fluids include devices for measuring and comparing the absorption of electromagnetic radiation by cellular and cell-free hemoglobin at two or more wavelengths in the Soret region. Systems and methods for determining erythrocyte membrane fragility include devices for measuring the concentration of at least one cell-free hemoglobin derivative, and using the absorption properties of cellular and cell-free hemoglobin derivatives in the Soret region.

A red cell membrane antigen magnetic bead kit and an application in blood type antibody test belong to the biological technical field, for using red cell membrane antigen magnetic beads to prepare a kit and provide the application in blood type antibody test. The kit comprises red cell membrane antigen magnetic beads, a U-shaped reaction plate of 96 holes and a red cell membrane antigen magnetic bead diluent. The invention has the advantages that the red cell membrane antigen magnetic beads have long storage period, thus is beneficial for the storage of red cell rare antigens.

The invention relates to the blood cell detection field and discloses a blood cell detection reagent, a blood cell processing method and a blood cell identification method. The blood cell detection reagent comprises fluorescent dye, a sphericized component and organic alcohol, wherein the fluorescent dye has cell permeability and can specially stain the nucleic acid substance in the cell; the sphericized component can sphericize red blood cells, keep the red cell membrane to be intact and cannot damage the internal structure of the white blood cell; the organic alcohol can enhance the cell permeability and aids the fluorescent dye to enter the cells. The invention also discloses a blood cell processing method and a blood cell identification method. According to the blood cell detection reagent and the method, one kind of reagent can detect different blood cells at one time, and can particularly detect juvenile white blood cells and reticulated red blood cells simultaneously, therefore, the detection cost is greatly saved, the detection speed is increased and the instrument complexity is reduced.

The present invention is directed to pegylated red blood cells comprising a polyethylene glycol (PEG) attached to a thiolated amino group on a membrane protein, and to compositions comprising the pegylated red blood cells. The invention also provides methods of preparing pegylated red blood cells comprising reacting red blood cells with a compound that produces a thiolated amino group on a red blood cell membrane protein, and reacting the thiolated red blood cell with a PEG. The invention further provides methods of treatment using pegylated red blood cells.

The invention provides application of an eye medicine wrapped with an erythrocyte membrane in preparation of an eye preparation, and also provides the eye preparation. The preparation is in a form of biodegradable nano particles wrapped with the erythrocyte membrane. The preparation has the advantages that the shortcomings of the traditional eye drops that partial removal is quickly realized, the bioavailability is low, the eye drops are absorbed by the whole body, and the side effect is difficult to avoid, are overcome; the time of the medicine standing in eyes is obviously prolonged; the controlled-released administration of the medicine is realized. Therefore, the bioavailability of the medicine is improved, the side effect on the whole body is reduced, and a new hope is brought to clinical ophthalmology on treatment of intraocular diseases.

The invention discloses an ELISA reagent box for checking irregular antibody in serum and the preparing way for the reagent. The reagent box comprises an enzyme link board, on which O mixed red cell membrane protein is wrapped, the membrane protein contains all red cell antigens; some negative serum, which is for negative comparison with human serum that has no agglutination reaction with the above red cells; and some positive serum, which is for positive comparison with human serum that has agglutination reaction with the above red cells. The principle of the invention is: no O spectrum red cell is used as detection reagent, in stead red cell membrane protein is extracted, wherein, the antigen containing red cell surface is wrapped on the enzyme link board; and enzyme linkage immunity analysis method (ELISA) is used to check whether a serum to be tested contains any irregular antibody. The advantages with the invention are: the long storage period, the high throughput, the easy to judge results and the simple detection method.

The invention discloses a preparation method and an application of an erythrocyte membrane-coated acid-sensitive polymer prodrug nano drug delivery system, wherein the polymer is formed by connecting sodium polyglutamate and carbocisteine through a peptide bond and then is bonded with an anti-cancer drug taxol to form the polymer prodrug; and the polymer prodrug is coated by an erythrocyte membrane to obtain an erythrocyte membrane-coated acid-sensitive polymer drug delivery system. The drug delivery system has the following characteristics that the particle size is about 100nm, and the shape is a sphere; the drug delivery system is relatively stable in a phosphate buffer and serum; the drug release character is relatively good in an acid environment; the toxicity is obviously reduced in cell experiments; the ingestion of the system by macrophage is obviously reduced; without destructive effect on erythrocyte, the system can be applied to intravenous injection; the circulating time of the system in blood is remarkably longer than that of polymer; and the system has an obvious inhibiting effect on the tumor growth of lung cancer.

Red blood cell membrane derived microparticles (RMP) are safe, economical, effective hemostatic agents in the treatment of a wide range of bleeding conditions and can be considered as universal hemostatic agents. RMP are produced from red blood cells using a high-pressure extrusion membrane shear process and can be lyophilized after production and retain activity even when stored at room temperature. RMP can be administered to original donors (autologous treatment), thus avoiding transfusion complications, or can be administered to blood type compatible recipients. RMP produced from type O, Rh negative red cells can be given to any person regardless of blood type. RMP can be administered to reduce excessive bleeding resulting from trauma, surgeries, invasive procedures and various bleeding disorders such as platelet disorders, either congenital or acquired, and coagulation disorders, either congenital or acquired.

The invention discloses a preparation method of a functional erythrocyte membrane. The preparation method is characterized in that 0.6 mg of erythrocyte membrane is dissolved into 1 ml of deionized water or phosphate buffer liquid, wherein the phosphate buffer liquid is NaH2PO4 and Na2HPO4, the pH (potential of Hydrogen) value is 7.4, and the concentration is 100 mM; and a membrane solution and DSPE-PEG-RGD are subjected to ultrasonic wave or stirring, and the functional erythrocyte membrane can be obtained. The preparation method is easy to operate, the final functional erythrocyte membrane can serve as a carrier material to transport drugs or biological molecules to conduct medical and cosmetology and serves as a decoration camouflage material to coat the surface of other materials to realize decoration and camouflage, accordingly, accumulation of nano materials or active biological molecules at specific parts is improved, and the treatment and application effects are enhanced.

The invention provides a bionic binary cooperative nano-carrier as well as a preparation method and an application thereof. The bionic binary cooperative nano-carrier comprises an erythrocyte membrane, glucose oxidase, iron-supporting ferritin nano-particles and a photosensitizer, wherein the glucose oxidase and the iron-supporting ferritin nano-particles are coated with the erythrocyte membrane,and the photosensitizer is embedded into the surface of the erythrocyte membrane or entrapped by the erythrocyte membrane. Chain stimulative responsibility coordination of tumor hunger therapy and chemical kinetic therapy is realized, two enzymes are conveyed to a target site of an organism with the carrier on the basis of biocompatibility of the erythrocyte membrane and tumor targeting of targeting molecules, accurate administration is realized by membrane rupture based on 808 nm near-infrared light illumination in the tumors, the problem of drug resistance is solved effectively, furthermore,systemic toxicity caused by drug application is remarkably reduced, and damage to other normal tissue in an in-vivo circulation process is prevented effectively. The invention further provides the preparation method of the bionic binary cooperative nano-carrier. The bionic binary cooperative nano-carrier and the preparation method have good application prospect.

The invention provides a bionic nanocarrier for treating GBM (glioblastoma) and a preparation method of the bionic nanocarrier and belongs to the field of biomedical engineering. According to the bionic nanocarrier for treating the GBM and the preparation method of the bionic nanocarrier, Ang-RBCm-CA / siRNA comprises Ang-RBCm (Ang (Angiopep-2) polypeptide modified red blood cell membrane) and citraconic anhydride grafted polylysine and polyethylenimine-siRNA compound (CA / siRNA). Ang-RBCm-CA / siRNA can effectively carry siRNA and protect siRNA against degradation. The Ang-RBCm-CA / siRNA has prolonged blood circulation time and high blood brain barrier penetrability, can be efficiently taken in by U87MG brain glial cells over-expressed by a low-density LPR (lipoprotein receptor) and can realizerapid charge conversion in endosome / lysosome, effectively release siRNA and effectively treat in-situ U87MG GBM.

The present invention is directed to pegylated red blood cells comprising a polyethylene glycol (PEG) attached to a thiolated amino group on a membrane protein, and to compositions comprising the pegylated red blood cells. The invention also provides methods of preparing pegylated red blood cells comprising reacting red blood cells with a compound that produces a thiolated amino group on a red blood cell membrane protein, and reacting the thiolated red blood cell with a PEG. The invention further provides methods of treatment using pegylated red blood cells.

The present invention discloses cryopreservation method of erythrocyte and its erythrocyte pretreating liquid and erythrocyte freeze protecting liquid. The method includes first hatching erythrocyte in erythrocyte pretreating liquid, then protecting erythrocyte in erythrocyte freeze protecting liquid and finally freezing erythrocyte. The erythrocyte pretreating liquid is basic buffering liquid with small molecular sugar component added, and the erythrocyte freeze protecting liquid is macro molecular protecting liquid with small molecular sugar and albumin component added. The present invention protects the inner erythrocyte membrane and outer erythrocyte membrane to raise erythrocyte recovering rate and lower the hemolysis rate of erythrocyte after thawing.

The present invention discloses calf blood deproteinizing extract, its eye ointment preparation and the preparation process. The preparation process of calf blood deproteinizing extract includes the following steps: collecting calf blood, separating erythrocyte, adding water to swell to destroy erythrocyte membrane and to release inside matter, pasteurization, ultrafiltering and concentration to obtain the intermediate; nano filtering to desalt, reverse penetration to concentrate and decolorizing to obtain calf blood deproteinizing extract. Adding proper amount of excipient and stabilizer into the calf blood deproteinizing extract obtains calf blood deproteinizing extract eye ointment preparation. The said preparation process has less loss of effective components and can maintain the bioactivity at most. The eye ointment preparation is used in treating keratitis, cornea ulcer and other eye diseases via promoting the restoring and regeneration of tissue.

The invention relates to a preparation method and application of an ultrasonic control type anti-tumor drug delivery system. The problems that existing tumor treatment drugs are low in drug loading capacity, are leaked when delivered, are low in tumor response sensitivity, slow in release and prone to causing drug resistance, and can not be controlled in vitro are solved effectively. The ultrasonic control type anti-tumor drug delivery system is established with hollow mesoporous titanium dioxide as the base body by being internally loaded with perfluorohexane and drug bleomycin, wrapped by an endogenous biological membrane-erythrocyte membrane and modified by tumor homing peptides; a nanoscale particle size distribution drug delivery system is prepared with hollow mesoporous titanium dioxide as the base body by being internally loaded with perfluorohexane and model drug bleomycin, wrapping surfaces of hollow mesoporous titanium dioxide by RBC, and being wrapped by an endogenous biological membrane-erythrocyte membrane; a tumor drug delivery system with a remote ultrasonic control function is established by modifying tumor homing peptide NGR tail ends with diacyl lipid.

The invention relates to the field of medicine chemical synthesis and in particular relates to a method for preparing erythrocyte membrane vesica coated prussian blue nanoparticles from prussian blue,erythrocyte membrane vesicae and a photosensitizer which is finally embedded, and specific methods of different steps. The method for preparing the erythrocyte membrane vesica coated prussian blue nanoparticles with the embedded photosensitizer Ce6 specifically comprises the following steps: (1) preparing prussian blue nanoparticles; (2) preparing erythrocyte membrane vesicae; (3) embedding the photosensitizer Ce6 into the erythrocyte membrane vesicae; and (4) coating the prussian blue nanoparticles with the erythrocyte membrane vesicae into which the photosensitizer is embedded. The composite nano medicine delivery system provided by the invention has the advantages that the circulation time of medicines in bodies is increased, a large medicine carrying amount is achieved, and high biocompatibility is achieved.

The invention provides a functional red blood cell targeting circulating tumor cells (CTCs) and belongs to the technical field of red blood cell modifying and circulating tumor cell catching. A functional molecule is embedded in a cytomembrane of the functional red blood cell; one end of the functional molecule is used as an embedded end and used for being embedded in the red cell membrane; the other end of the functional molecule is used as a targeting end, the targeting end is used as a CTCs targeting antibody or folic acid and can specifically recognize and be combined with CTCs surface biomarkers; and the embedded end of the functional molecule is connected with the targeting end of the functional molecule through polyethylene glycol (PEG) to form the functional molecule with an "embedded end-PEG-targeting end" structure. The functional red blood cell can recognize, catch or inhibit the CTCs, is used for specific recognition and catching research for microscale CTCs of blood samples of clinic patients in vitro and adjusting and controlling activity of caught CTCs, and therefore the application prospect is developed on forecast and precaution of tumor metastasis.

The invention relates to a method for accurately and rapidly detecting antigens and antibodies in human serum in a trace mode. The method comprises the steps of preparing trace (1ml) known anti-erythrocyte antigen and antibody on a trace detection plate by utilizing an immunohematology principle, adding trace (1ml) unknown erythrocytes to be detected, and detecting the antigens on the surface of the erythrocyte membrane; or adding trace (1ml) unknown serum to be detected into the erythrocytes with the known trace (1ml) erythrocyte antigen, and detecting the antigens and antibodies on the surface of the erythrocyte membrane in the human blood. The reaction identifier is collected by the erythrocytes, the reaction with the collected erythrocytes is a positive reaction, the reaction without the collected erythrocytes is a negative reaction, the method is combined with a centrifugal machine, a spectrophotometer, a microscope and computer programs, and the erythrocyte antigens and the antibodies in the serum can be rapidly, accurately and automatically detected. According to the trace detection plate kit, the safety, high efficiency and accuracy of the clinical erythrocyte zygosity can be greatly improved, the detection cost is reduced, and the development of clinical hematology application is promoted.

The present invention relates to methods, combinations and pharmaceutical compositions for treating or preventing a hemolytic disease or condition in a mammal, wherein: said hemolytic disease or condition is caused by an attack of said mammal's red blood cells by said mammal's own body, or said mammal is a pregnant mammal and said hemolytic disease or condition of a fetus of said pregnant mammal is caused by an attack of said fetus' red blood cells by an antibody of said pregnant mammal, or said mammal is a baby and said hemolytic disease or condition of said baby is caused by an attack of said baby's red blood cells by an antibody of said baby's mother. The exemplary hemolytic diseases or conditions include hemophagocytic lymphohistiocytosis, an autoimmune disease or condition, or a hereditary hemolytic disease or disorder.

The invention discloses a series of urea transporter inhibitors of which the structural formula is disclosed in the specification. An erythrocyte model is used for screening to obtain compounds for inhibiting urea transporters. The experimental result indicates that the compounds (such as Youti) can inhibit the permeation of urea transporter UT-B mediated erythrocyte membranes for urea, and the action forms a dosage dependency relationship; Youti within effective dose range has no cytotoxic action on the MDCK (Madin-Darby Canine Kidney) cells, which indicates that the action of Youti for inhibiting cell permeable urea is irrelevant to cytotoxicity; the inhibiting action of Youti on the urea transporter UT-B gradually increases; the inhibiting action of Youti on the urea transporter UT-B is reversible; and the in-vivo test result proves that Youti can obviously increase the uresis amount of a rat, lower the concentration of urea in the urine of the rat, and lower the osmotic pressure, which indicates that Youti has selective diuresis action on urea in vivo.

The invention belongs to the technical field of pharmacy and particularly relates to an erythrocyte membrane-encapsulated tetrandrine PLGA nanoparticle and a preparation method and application thereof. The nanoparticle structurally includes an erythrocyte membrane, PLGA and tetrandrine, the tetrandrine is combined with PLGA to form a tetrandrine-PLGA nanocore, and the erythrocyte membrane is encapsulated outside the tetrandrine-PLGA nanocore. The preparation method is simple and efficient. The nano preparation improves the biocompatibility of a whole drug delivery system, long circulation andsustained release of the tetrandrine in the human body are achieved, toxic and side effects caused by too high blood medicine peak concentration of common injections are avoided, and the nanoparticlehas a good application prospect.

Red blood cell membrane derived microparticles (RMP) are safe, economical, effective hemostatic agents in the treatment of a wide range of bleeding conditions and can, therefore, be considered as universal hemostatic agents. Effective RMP are produced from red blood cells using a high-pressure extrusion membrane shear process. The RMP can be lyophilized after production and retain activity even when stored at room temperature. RMP can be administered to original donors (autologous treatment), thus avoiding transfusion complications, or can be administered to blood type compatible recipients. RMP produced from type O, Rh negative red cells can be given to any person regardless of blood type. RMP can be administered to reduce excessive bleeding resulting from trauma, surgeries, invasive procedures and various bleeding disorders such as platelet disorders, either congenital or acquired, and coagulation disorders, either congenital or acquired. Administration of RMP prepared according to the invention demonstrates effectiveness in safely reducing bleeding.

The invention provides a bionic nanometer erythrocyte genophore and a preparation method and application thereof. The bionic nanometer erythrocyte genophore comprises an erythrocyte membrane and a kernel which is wrapped by the erythrocyte membrane and can achieve charge reversal. The invention further the preparation method of the bionic nanometer erythrocyte genophore. The method comprises the steps that the genophore which can achieve charge reversal is synthesized through an amide reaction; then, the kernel of the genophore which can achieve charge reversal is wrapped by the erythrocyte membrane through an extrusion method. According to the bionic nanometer erythrocyte genophore, a biological membrane wrapping treatment gene is applied to disease treatment for the first time, the electronegativity of the kernel can be guaranteed, the gene is successfully wrapped by the erythrocyte membrane, long circulation of gene medicine in vivo is achieved, and the charge reversal can be achieved under the focus microenvironment, and accordingly nucleic acid medicine is released. Meanwhile, the genophore is free of cytotoxicity, non-toxic metabolism in vivo can be completed, the brand-new,safe and efficient genophore is provided for gene treatment, and the genophore has wide application prospects.

The invention discloses a blood group antigen chip and application thereof in detection of unexpected erythrocyte antibodies. The detection comprises: (1) coating a carrier with a blood group erythrocyte membrane antigen; (2) contacting a tested sample with the antigen of the carrier; (3) adding a second antibody labeled with a marker; and (4) performing signal detection on the marker. The blood group antigen chip and a detection method of unexpected erythrocyte antibodies are high in sensitivity, good in accuracy, independent of erythrocytes, and capable of detecting binding antibodies of a plurality of rare blood group antigens.

The invention discloses an erythrocyte membrane coated bionic blood hexavalent chromium reduction remover / magnetic nanomotor and a preparation method and application thereof. By electrostatic self-assembly, magnetic ferroferric oxide particles are externally coated with mesoporous silica through hexadecyl trimethyl ammonium bromide serving as a template agent, then step-by-step modification of ammonium-rich organics and reducing substances in mesoporous passages is performed, and finally, erythrocyte membranes are adopted for coating to obtain the bionic blood hexavalent chromium reduction remover / magnetic nanomotor with high biocompatibility. The reduction remover / magnetic nanomotor is capable of freely getting in and out of erythrocytes, proper movement of the nanomotor in the erythrocytes can be controlled through an external alternating magnetic field so as to realize complete contact between the remover and hexavalent chromium in the erythrocytes, the hexavalent chromium is reduced into low-toxicity trivalent chromium by a reducing agent, and then the trivalent chromium is captured under the trivalent chromium complexing action of the ammonium-rich organics in the mesoporous passages, so that sequential reduction and removal of chromium in blood is realized.

The present invention relates to methods, combinations and pharmaceutical compositions for supplying a blood source from a donor source with a mis-matched blood type, or potentially a mis-matched blood type, to a recipient, using, inter alia, an effective amount of a nanoparticle comprising a) an inner core comprising a non-cellular material, and b) an outer surface comprising a cellular membrane derived from a red blood cell, the cellular membrane of the nanoparticle comprising a blood type antigen that exists on the red blood cell from the donor source, but is missing or potentially missing on red blood cells of the recipient.